Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2024-12-20 DOI:10.1002/cam4.70484

Youzhao Ma, Jingyang Zhang, Dechuang Jiao, Xiuchun Chen, Zhenzhen Liu

{"title":"Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy","authors":"Youzhao Ma, Jingyang Zhang, Dechuang Jiao, Xiuchun Chen, Zhenzhen Liu","doi":"10.1002/cam4.70484","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Few studies with a large sample size are available on patients with metabolic syndrome (MetS) receiving neoadjuvant treatment (NAT) for breast cancer. This study aimed to investigate the impact of MetS on the prognosis of patients with breast cancer undergoing NAT.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The data of patients with breast cancer receiving NAT at our center from January 2017 to December 2019 were retrospectively analyzed. A chi-square test and logistic regression model were applied to ascertain the factors associated with MetS and pathological complete response (pCR). The Cox proportional risk model was employed for univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 910 patients enrolled, 164 (18.0%) were diagnosed with MetS, 568 (62.4%) with stage II, and 342 (37.6%) with stage III. Postmenopausal status (<i>p</i> = 0.045) and stage III (<i>p</i> = 0.009) were associated with a higher incidence rate of MetS. MetS was associated with a lower pCR rate (<i>p</i> = 0.027). The 5-year DFS (83.7% vs. 73.1%, <i>p</i> = 0.001) and OS (92.8% vs. 85.5%, <i>p</i> = 0.001) of the non-MetS group were significantly better than those of the MetS group. In premenopausal women, the DFS (<i>p</i> = 0.001) and OS (<i>p</i> = 0.025) of the non-MetS group were significantly better than those of the MetS group. No significant differences were noted in DFS (<i>p</i> = 0.270) or OS (<i>p</i> = 0.078) between the two groups in postmenopausal women. In the Cox proportional risk model, MetS acted as an independent factor associated with DFS (HR = 1.705, 95% CI: 1.201–2.421, <i>p</i> = 0.003) and OS (HR = 1.874, 95% CI: 1.149–3.055, <i>p</i> = 0.012).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>MetS was associated with poor prognosis in patients with breast cancer receiving NAT. Hence, close attention should be paid to patients with breast cancer who have MetS.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 24","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70484","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70484","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Few studies with a large sample size are available on patients with metabolic syndrome (MetS) receiving neoadjuvant treatment (NAT) for breast cancer. This study aimed to investigate the impact of MetS on the prognosis of patients with breast cancer undergoing NAT.

Methods

The data of patients with breast cancer receiving NAT at our center from January 2017 to December 2019 were retrospectively analyzed. A chi-square test and logistic regression model were applied to ascertain the factors associated with MetS and pathological complete response (pCR). The Cox proportional risk model was employed for univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS).

Results

Of the 910 patients enrolled, 164 (18.0%) were diagnosed with MetS, 568 (62.4%) with stage II, and 342 (37.6%) with stage III. Postmenopausal status (p = 0.045) and stage III (p = 0.009) were associated with a higher incidence rate of MetS. MetS was associated with a lower pCR rate (p = 0.027). The 5-year DFS (83.7% vs. 73.1%, p = 0.001) and OS (92.8% vs. 85.5%, p = 0.001) of the non-MetS group were significantly better than those of the MetS group. In premenopausal women, the DFS (p = 0.001) and OS (p = 0.025) of the non-MetS group were significantly better than those of the MetS group. No significant differences were noted in DFS (p = 0.270) or OS (p = 0.078) between the two groups in postmenopausal women. In the Cox proportional risk model, MetS acted as an independent factor associated with DFS (HR = 1.705, 95% CI: 1.201–2.421, p = 0.003) and OS (HR = 1.874, 95% CI: 1.149–3.055, p = 0.012).

Conclusion

MetS was associated with poor prognosis in patients with breast cancer receiving NAT. Hence, close attention should be paid to patients with breast cancer who have MetS.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

研究目的针对接受乳腺癌新辅助治疗（NAT）的代谢综合征（MetS）患者的大样本量研究很少。本研究旨在探讨代谢综合征对接受新辅助治疗的乳腺癌患者预后的影响：回顾性分析2017年1月至2019年12月在本中心接受NAT治疗的乳腺癌患者数据。应用卡方检验和逻辑回归模型确定MetS与病理完全反应（pCR）的相关因素。采用Cox比例风险模型对无病生存期（DFS）和总生存期（OS）进行单变量和多变量分析：在入组的 910 名患者中，164 人（18.0%）被确诊为 MetS，568 人（62.4%）为 II 期，342 人（37.6%）为 III 期。绝经后状态（p = 0.045）和 III 期（p = 0.009）与 MetS 发病率较高有关。MetS 与较低的 pCR 率相关（p = 0.027）。非 MetS 组的 5 年 DFS（83.7% 对 73.1%，p = 0.001）和 OS（92.8% 对 85.5%，p = 0.001）明显优于 MetS 组。在绝经前妇女中，非 MetS 组的 DFS（p = 0.001）和 OS（p = 0.025）明显优于 MetS 组。两组绝经后妇女的 DFS（p = 0.270）和 OS（p = 0.078）无明显差异。在 Cox 比例风险模型中，MetS 是与 DFS（HR = 1.705，95% CI：1.201-2.421，p = 0.003）和 OS（HR = 1.874，95% CI：1.149-3.055，p = 0.012）相关的独立因素：MetS与接受NAT治疗的乳腺癌患者的不良预后有关。结论：接受 NAT 治疗的乳腺癌患者的预后较差与 MetS 相关，因此应密切关注有 MetS 的乳腺癌患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.